Cargando…

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth

Oncogenic RAS mutant (RAS(MUT)) proteins have been considered undruggable via conventional antibody regimens owing to the intracellular location restricting conventional-antibody accessibility. Here, we report a pan-RAS–targeting IgG antibody, inRas37, which directly targets the intracellularly acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Seung-Min, Kim, Ji-Sun, Park, Seong-Wook, Jun, Sei-Yong, Kweon, Hye-Jin, Choi, Dong-Ki, Lee, Dakeun, Cho, Yong Beom, Kim, Yong-Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962039/ https://www.ncbi.nlm.nih.gov/pubmed/31998840 http://dx.doi.org/10.1126/sciadv.aay2174

Ejemplares similares

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
por: Shin, Seung-Min, et al.
Publicado: (2017)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo
por: Rackley, Briana, et al.
Publicado: (2021)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

VPS35 binds farnesylated N-Ras in the cytosol to regulate N-Ras trafficking
por: Zhou, Mo, et al.
Publicado: (2016)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3
por: Ahn, Sung Yong, et al.
Publicado: (2017)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

The Importance of Mg(2+)‐Free State in Nucleotide Exchange of Oncogenic K‐Ras Mutants
por: Pálfy, Gyula, et al.
Publicado: (2022)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation
por: Aylon, Yael, et al.
Publicado: (2009)

The effects of mutant Ras proteins on the cell signalome
por: Takács, Tamás, et al.
Publicado: (2020)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line
por: Tokunaga, T, et al.
Publicado: (2000)

ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant
por: Tago, Kenji, et al.
Publicado: (2017)

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
por: Khan, Imran, et al.
Publicado: (2022)

REDD1 loss reprograms lipid metabolism to drive progression of RAS mutant tumors
por: Qiao, Shuxi, et al.
Publicado: (2020)

Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors
por: Clavaín, Laura, et al.
Publicado: (2022)

BR2 cell penetrating peptide effectively delivers anti-p21Ras scFv to tumor cells with ganglioside expression for therapy of ras-driven tumor
por: Yu, Ting, et al.
Publicado: (2022)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
por: Scharpf, Robert B., et al.
Publicado: (2022)

Oncogenic Ras mutant causes the hyperactivation of NF‐κB via acceleration of its transcriptional activation
por: Tago, Kenji, et al.
Publicado: (2019)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Ras Effector Mutant Expression Suggest a Negative Regulator Inhibits Lung Tumor Formation
por: Vandal, Guillaume, et al.
Publicado: (2014)

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity
por: Hong, Sungpyo, et al.
Publicado: (2023)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Hair follicle regeneration suppresses Ras-driven oncogenic growth
por: Pineda, Cristiana M., et al.
Publicado: (2019)

Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway
por: Wu, C-H, et al.
Publicado: (2002)

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
por: Yang, Hang, et al.
Publicado: (2022)

Injury prevents Ras mutant cell expansion in mosaic skin
por: Gallini, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_12e48n6sbdar6mklepaihr5cd1